NCT05874037View on ClinicalTrials.gov

Fluvoxamine for Long COVID-19

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

May 15, 2025

Study Completion Date

May 15, 2025

Conditions
Long COVID
Interventions
DRUG

Fluvoxamine

Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Balvi COVID Fund

UNKNOWN

collaborator

BJH Townley Fund

UNKNOWN

lead

Washington University School of Medicine

OTHER